Human Genome Sciences and its partner GlaxoSmithKline revealed that the high dose of their experimental lupus therapy demonstrated a statistically......
Recommended Sources
Recommended Publications
About Pharma Industry
BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.
Web Buzz:
-
Efficacy at Ph III: lupus drug Benlysta confirms blockbuster potential
In-Pharma Technologist - 22 days 16 hours 37 minutes ago
The findings unlock the potential $3bn (€2bn) a year lupus market, which while significant for UK drug major GlaxoSmithKline, is potentially...
-
Human Genome, Glaxo lupus drug works in 2nd trial
Reuters -
22 days 17 hours 25 minutes ago
By Toni Clarke BOSTON (Reuters) - Human Genome Sciences Inc said on Monday its experimental lupus drug Benlysta was successful in a second large...
- Novartis Looks at Combination Pills to Fix Hypertension Franchise
- Study Showing Drug Ads Are Linked to Higher Prices Has Flaws
- Bankers Reveal Top Biotech IPO Contenders; New Filer Ironwood Among Them
- Pfizer Got $160M in Tax Money to Build in Connecticut
- Sanofi's Viehbacher Backs Health Reform; May Change Company's Name
- Viagra Now Available Intravenously
- Genzyme Kidney Drug Failed, Too...What Could Possibly Happen Next?
- Peter Pitts' CMPI Targeted Over Anti-Healthcare Reform Video Game
- Why Allergan and Medicis Should Embrace the "Botox Tax" in Senate Health Bill
- Why J&J's Stelara Launch Should Target Dermatologists First
- NHS Loses Fight Over Publication of Antipsychotic Meds Brochures for Kids
- Genzyme's Termeer Got $50M in Compensation Over Last 3 Years; Wife Got Trips to Asia on Corporate Jet
- Merck Gives Snapshot of Combined Company: $47B in Sales; Just $7.6B in Cash
- Why Pfizer Wants Your Car-Sick Dog to Travel on Thanksgiving
- FDA Delays Genzyme's Lumizyme, Manufacturing Problems Blamed
- Will FDA Approve MannKind's Insulin Inhaler?
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Hepatitis C Drugs Kill the Virus...and Your Sex Drive
- Microchip Implant to Link Your Health Records, Credit History, Social Security
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
- NYT's MannKind Story Needlessly Quoted a Competitor Bashing Afresa
- Novartis CEO Sends Emails to 140 Animal Rights Activists:
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- How NOT to Write a Biotech Press Release: Just Ask Epeius
- The 10 Weirdest Drug Stories of the Month
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity"
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching
Industry Transcripts by Seeking Alpha
- How to choose the right insurance carrier for your business
- Real Estate: Prepare your properties to weather what lies ahead
- Technology: Be prepared if part of your global supply chain goes missing
BNET User Analysis